Jagsonpal Pharma

Jagsonpal Pharmaceuticals reported a strong recovery in Q4 FY26, with revenue growing 10% year-on-year to INR64 crores. This performance was driven by sharpened execution focus, particularly in MR productivity and retention. EBITDA grew 9% year-on-year to INR11 crores, maintaining stable margins at 16%, while PAT saw a sharper uptick, rising 31% year-on-year to INR9 crores, with a margin expansion to 14%.

For the full fiscal year 2026, revenue grew modestly at around 7% to INR287 crores. Despite this, net profit grew significantly by 19% to INR45 crores, demonstrating strong financial discipline. The company outperformed the Indian Pharma Market (IPM) which grew 7-8% during Q4 and most of the year, with Jagsonpal's MAT growth at 12.2% (3.6% above market) and Q4 growth at 14.2% (against IPM's 10.5%).

The company's strategic priorities include driving organic growth through enhanced MR productivity, sharper brand focus, and disciplined cost management. Key growth anchors were Gynaecology and Dermatology, which showed strong traction and improved prescription conversion. Management aims to achieve 1.5x IPM growth, translating to a 12-15% revenue growth target for FY27 and beyond, supported by new product launches and rejuvenation of older brands.

Jagsonpal's board approved a INR40 crores share buyback at INR250 per share, with promoters not participating, expected to increase ROE from 16% to 18% and ROCE from 22% to 26%. Additionally, a 200% dividend was recommended, including a 75% special dividend, resulting in a total payout of INR4 per share or approximately INR26 crores. Combined, these initiatives represent a return of over INR66 crores to shareholders, reflecting confidence in the business model and cash generation.

The company maintains a strong and balanced portfolio, with its top 10 brands contributing 58-60% of total sales, and nine of these ranked within the top five in their categories. In FY26, six new products and three SKUs were launched. For FY27, the company plans to launch 9-10 new products, with about half focused on rejuvenating existing legacy brands and the remainder in new product therapies within Gynaec, Ortho, and Derma.

While Q4 gross margins saw a slight decline due to product mix, the full-year gross margin remained stable at 64.2%. Other expenses marginally increased by 30 basis points, primarily due to timing issues rather than structural changes. The company believes its strong gross margins (65-80% for branded companies) and ability to implement 10% price increases will help absorb cost pressures, particularly from packaging materials, without significantly impacting overall profitability.